Drug Shortage Report for BIVALIRUDIN FOR INJECTION
Report ID | 149848 |
Drug Identification Number | 02435268 |
Brand name | BIVALIRUDIN FOR INJECTION |
Common or Proper name | Bivalirudin for Injection 250 mg/vial SD Vial 10 mL |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | BIVALIRUDIN |
Strength(s) | 250MG |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 10 mL |
ATC code | B01AE |
ATC description | ANTITHROMBOTIC AGENTS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2021-11-24 |
Actual start date | 2021-11-24 |
Estimated end date | 2022-01-20 |
Actual end date | 2022-01-21 |
Shortage status | Resolved |
Updated date | 2022-02-04 |
Company comments | Sandoz is an alternate supplier of Bivalirudin for Injection and have been informed of our impending supply interruption. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v9 | 2022-02-04 | French | Compare |
v8 | 2022-02-04 | English | Compare |
v7 | 2021-12-24 | French | Compare |
v6 | 2021-12-24 | English | Compare |
v5 | 2021-12-03 | French | Compare |
v4 | 2021-12-03 | English | Compare |
v3 | 2021-11-25 | English | Compare |
v2 | 2021-11-24 | French | Compare |
v1 | 2021-11-24 | English | Compare |
Showing 1 to 9 of 9